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during face-to-face interviews with a minimum representative sample (n= 100) of 
the general population, per-country, in Australia, Canada, France, Japan, Spain and 
the UK. Visual Analog Scale (VAS) scores were obtained to validate TTO scores. TTO 
scores were converted into utility values. Results: The highest mean TTO utility 
scores (range 0.66-0.82) were observed for the anchor HS (minimal disease activity) 
across all countries. All flare HS were associated with a disutility compared with the 
anchor HS: mild flare HS (0.55-0.71), moderate flare HS (0.38-0.53), severe renal flare 
HS (0.33-0.45), severe Central Nervous System (CNS) flare HS (0.30-0.45) and severe 
generalised flare HS (0.19-0.33). Significant differences were reported between the 
anchor state and each flare state across all countries (p< 0.05). Mean VAS scores 
followed the same trend. The severe generalised flare HS received the lowest mean 
TTO utility score across all six countries suggesting that the perceived day-to-day 
impact of a severe generalised flare was greater than a severe CNS or severe renal 
flare. ConClusions: These results show that a decrease in utility, representing a 
detrimental impact on HRQoL, was observed with increasing severity of flare. These 
results could be applied in cost-utility analyses for interventions for SLE.
QL2
The ImpacT of DIscrImInaTIon, VIcTImIzaTIon anD socIaL sTanDIng on 
heaLTh-reLaTeD QuaLITy of LIfe
Samnaliev M.
Boston Childrens Hospital, Boston, MA, USA
objeCtives: To examine the link between discrimination, victimization and social 
standing on health-related quality of life (HRQL). This information is currently not 
known, but is crucial as it can aid decision makers in the design of cost-effective pol-
icies to reduce such victimization among specific minority populations. Methods: 
We used data from 6,194 females and males from a prospective cohort of youth 
that has been tracked for over 15 years. We specifically examined the impact of 
discrimination, victimization and social standing of sexual orientation minorities 
on their HRQL (using EQ-5D-5L). In 2013, participants reported sexual orientation 
(Completely Heterosexual [CH], Mostly Heterosexual [MH], Bisexual [B], and Lesbian/
Gay [LG])). Participants previously reported past-year bullying victimization and 
discrimination (range: 1 [never] to 5 [several times/week]) and self-perceived social 
standing (range: 1 [top] to 10 [bottom]) in adolescence. Longitudinal, multivariable 
linear regression models were used to assess the effect of bullying and social stand-
ing in adolescence on sexual orientation HRQL score disparities in young adult-
hood, controlling for gender and age. Results: Compared to CHs, sexual minorities 
reported more bullying and lower social standing in adolescence and lower HRQL 
in young adulthood: MH HRQL score= 0.880; B 0.845; LG 0.870 vs. CH 0.916 (all differ-
ences had p-values< 0.05). When discrimination, victimization and social standing 
were added to the multivariable models, orientation-group effect estimates were 
attenuated ~10%, suggesting adolescent bullying and lower social standing partly 
explained HRQL disparities in young adulthood. ConClusions: Our findings are 
a proof of concept that victimization is not only a social justice issue but imposes 
an economic burden on society, as evidenced by its impact on HRQL.Our findings 
can also be used in cost-effectiveness analyses of interventions to reduce stigma 
against sexual orientation minorities.
QL3
QuaLITy of LIfe DecremenTs afTer sTroke
Dewilde S.1, Thijs V.2, Annemans L.3, Peeters A.4, Belgian Stroke Council N.P.5
1SHE, Brussels, Belgium, 2KULeuven, Leuven, Belgium, 3Ghent University & Brussels University, 
Ghent, Belgium, 4Cliniques Universitaires Saint-Luc, Bruxelles, Belgium, 5Virga Jesseziekenhuis, 
Hasselt, Belgium
objeCtives: To quantify which factors affect the quality of life valuations (QoL) of 
patients after stroke. Methods: 569 ischemic stroke patients were recruited into 
a retrospective, observational study in 10 teaching and regional hospitals across 
Belgium. Patients were stratified according to their modified Rankin Score (mRS) 
ranging from 0 (full health) to 5 (severely dependent). QoL as measured by the EQ5D 
and the VAS were collected for their health status before and after the index stroke. 
Utility decrements were calculated and using a general linear model the relationship 
between a set of variables and quality of life evaluation and its decrement associ-
ated with the stroke experience was investigated. Different distributions and link 
functions were tested against each other using the AICC and BIC criterion. Results: 
Stroke had a significant effect on patient’s QoL: a positive relationship with the 
degree of disability was found: EQ5D decrements were 0.08, 0.17, 0.25, 0.40, 0.64 and 
0.75 for mRS categories 0 to 5; and equivalent decrements on the VAS scale were 
7, 11, 20, 27, 33 and 39. The EQ5D and VAS decrements were significantly related 
to each other (r= 0.49, p< 0.001) and the decrements were also correlated with their 
baseline values (r= -0.74 for EQ5D baseline measurement and its decrement; r= -0.55 
for VAS baseline value and decrement, p< 0.001). The decrements were of higher 
magnitude when measured by the EQ5D compared to the VAS. Furthermore the 
utility decrements were significantly associated with being female, being diabetic, 
having atrial fibrillation, being in a wheelchair, experiencing a change in one’s living 
situation and the number of days spent in an inpatient care facility during the first 
3 months after stroke. ConClusions: Stroke results in a significant decrease in 
patient’s QoL, the magnitude of which is related to patient characteristics, disease 
severity measures, clinical risk factors and living circumstances.
Ql4
DIfferences BeTween hypoTheTIcaL anD experIence-BaseD VaLue seTs 
for eQ-5D: ImpLIcaTIons for DecIsIon makers
Aronsson M., Husberg M., Kalkan A., Eckard N., Alwin J.
Linköping University, Linköping, Sweden
objeCtives: The aim of the study was to analyse the differences between hypo-
thetical and experience-based EQ-5D value sets. Furthermore, the aim was to evalu-
ate the health economic implications of such differences for policy decisions in 
health care. Methods: We studied the differences in hypothetical and experience-
based value sets using three different methods: numerical comparison, empirical 
Replicating a published regression predicting EQ-5D based on Health Assessment 
Questionnaire (HAQ) and Psoriasis Area and Severity Index (PASI) scores, however, 
led to subtle yet statistically significant differences in coefficients (Gray EQ-5D = 
0.782 -0.196xHAQ -0.00227xPASI vs. Rowen EQ-5D = 0.816 -0.220xHAQ –0.0231xPASI). 
In this analysis the Rowen algorithm was more sensitive to changes in disease sta-
tus, which is potentially important in a disease area with multiple available thera-
pies. ConClusions: The choice of mapping algorithm has the potential to affect 
the results of analyses performed. Although mean values obtained from different 
mapping algorithms may be similar, regression coefficients were shown to differ by 
mapping algorithm. Analyses using all available mappings should be presented to 
avoid accusations of ‘cherry picking’ the most favourable estimate. When suggesting 
the most appropriate analysis, clear justification should be provided.
pr3
InVesTIgaTIng The ImpacT of perspecTIVe on weIghTIng QaLys:  
a DIscreTe choIce experImenT
Butt T.1, Longworth L.2, Rubin G.1, Orr S.1
1University College London, London, UK, 2Brunel University, Uxbridge, UK
objeCtives: Discrete choice experiments (DCEs) are increasingly used to elicit 
preferences for weighting QALYs by other characteristics. Recent studies for weight-
ing QALYs have asked respondents to take the role of decision maker and prioritize 
treatment options for groups of patients (‘someone else’). The procedure normally 
used to obtain preferences for health states is for respondents to consider oneself in 
that state from behind a veil of ignorance. The aim of this study was to elicit public 
preferences for weighting QALYs by other characteristics, and to test if the decision-
maker perspective or naming the condition is equivalent to choosing for oneself 
from behind a veil of ignorance. Methods: A DCE was developed with attributes 
for health gain, severity, unmet need and process of care. Four questionnaires were 
designed to reflect three different perspectives and one alternative framing: a) ‘one-
self’ b) ‘someone like oneself’ c) ‘someone else’ d) ‘someone else’ with a disease label 
(age-related macular degeneration). 800 members of the public were recruited via an 
online survey panel, with 200 completing each of the four questionnaires. Results 
were analysed using a conditional logit model and utility weights derived using 
Hicksian compensating variation. Results: Attributes of health gain, severity and 
process of care were significant for all perspectives (p< 0.05). Respondents preferred 
treatments that offered greater health gain, for a higher severity (lower starting 
level of health), and more convenient process. Unmet need was significant only in 
the ‘oneself’ perspective with respondents preferring treatments that addressed 
an unmet need. ConClusions: Members of the public are willing to trade health 
gain for other characteristics. These include severity, process of care, and in some 
cases unmet need. There is evidence that preferences for weighting QALYs vary by 
perspective. The study may help inform criteria for decision-making when prioritiz-
ing health care resources.
pr4
VaLuIng eQ-5D-5L: Does The orDerIng of The heaLTh DImensIons 
ImpacT on heaLTh sTaTe VaLuaTIons?
Mulhern B.1, Shah K.2
1University of Sheffield, Sheffield, UK, 2Office of Health Economics, London, UK
objeCtives: Health states defined by multi-attribute instruments such as the 
EQ-5D-5L can be valued using Time Trade Off (TTO) or Discrete Choice Experiment 
(DCE) methods. A key feature of the tasks is the order in which the health state 
dimensions are presented to respondents. This is because respondents may use 
a variety of heuristics to answer the questions (for example focusing on the first 
dimension presented), and therefore the order of the dimensions may impact on 
the importance assigned to particular health state descriptions. The objective of 
this study is to assess the impact of different EQ-5D-5L dimension orderings on 
health state valuations. Methods: Preferences for EQ-5D-5L health states were 
elicited from a broadly representative sample of members of the UK general public. 
Respondents were allocated to one of three EQ-5D-5L dimension orderings, and 
completed 10 TTO and 9 DCE tasks via a computer assisted personal interview 
carried out in their home. Differences in mean values and the relative importance 
of the coefficients across the arms were compared using difference testing and 
regression analyses. Results: Descriptive analysis suggests that there are minimal 
differences between the mean TTO health state values across the different dimen-
sion orderings. Regression analysis suggests that the magnitude of the dimension 
coefficients differs across the different dimension orders (for both TTO and DCE), 
but there is no clear pattern. ConClusions: There is some evidence that the 
order in which the dimensions are presented impacts on the coefficients, which may 
impact on the health state values provided. The order of dimensions is an important 
consideration in the design of health state valuation studies.
QuaLITy of LIfe anD uTILITy sTuDIes
QL1
eLIcITaTIon of heaLTh sTaTe uTILITIes assocIaTeD wITh VaryIng 
seVerITIes of fLare In sysTemIc Lupus eryThemaTosus
Hartz S.1, Liu-Leage S.2, Paget M.A.2, Pollard C.3, Cook J.3, Enstone A.3
1Lilly Research Centre, Surrey, UK, 2Lilly France, Cedex, France, 3Adelphi Values, Bollington, UK
objeCtives: Systemic Lupus Erythematosus (SLE) is characterised by fluctuat-
ing periods of minimal disease activity and ‘flare’. Flare is an important outcome 
variable impacting the economic and humanistic burden of SLE. The objective of 
this study was to obtain population-based utility values for varying severities of 
flare to measure the impact on health-related quality of life (HRQoL). Methods: 
Six health states (HS) for varying severities of flare were developed based on lit-
erature, patient blogs, and interviews with patients (n= 12), rheumatologists (n= 7) 
and nurses (n= 2). HS were verified by independent clinical experts (n= 6) and pilot 
interviews (n= 10, UK). HS were evaluated using the time-trade-off (TTO) method 
A332  VA L U E  I N  H E A LT H  1 7  ( 2 0 1 4 )  A 3 2 3 – A 6 8 6  
pDB3
regIonaL assessmenT of seVere hypogLycemIc coma eVenTs In 
fInLanD
Vattulainen P.1, Mushnikov V.1, Hoti F.1, Saukkonen T.2, Korhonen P.1
1EPID Research, Espoo, Finland,, 2Novo Nordisk Farma, Espoo, Finland
objeCtives: In a previous study about severe hypoglycemic coma events (SH) 
among diabetes mellitus (DM) patients we saw regional variation in SH occurrence. 
The purpose was to compare the incidence of SH between hospital districts in 
Finland. Methods: This study among type 1 (T1) and 2 (T2) diabetic patients was 
based on nationwide health care registers. The study cohort contained insulin naïve 
diabetic patients who had filled at least one prescription of insulin during follow-up 
in 2006-2009. SH was defined as a hospitalization or a secondary health care visit 
due to hypoglycemic coma (ICD-10: E10.00 and E11.00). Stratified incidence rates and 
adjusted hazard ratio (HR) estimates with 95% confidence intervals (CI) were calcu-
lated. Analyses were performed for the first and recurrent SHs. Results: The popu-
lation comprised 5271 (17.6%) patients with T1 and 24602 (82.4%) with T2. Altogether 
3.1% patients experienced at least one SH during the follow-up. In different hospital 
districts the rate of first SHs varied from 5.6 (Varsinais-Suomi) to 47.8 (Länsi-Pohja) 
for T1, and from 4.8 (Pohjois-Karjala) to 50.3 (Länsi-Pohja) for T2. Compared to the 
capital area, the risks of first SHs varied differently for T1 and T2, but were com-
monly higher in Länsi-Pohja (T1: HR 3.46, CI 1.41-8.46; T2: HR 1.60, CI 1.13-2.29) and 
lower in Pohjois-Karjala (T1: no events; T2: HR 0.275, CI 0.14-0.56). Taking all SH 
events into account did not change these differences remarkably. ConClusions: 
We found differences between regions in risk of hospital-treated SH in both DM 
types. Further analyses will be performed for e. g. ambulance density.
pDB4
hIpos-er (hypogLycemIa In porTugaL oBserVaTIonaL sTuDy – 
emergency room): cLInIcaL ouTcomes In aDmITTeD paTIenTs
Conceição J.1, Dores J.2, Araújo F.3, Laires P.1, Carr R.4, Brodovicz K.5, Radican L.6, Nogueira 
A.M.1
1Merck Sharp & Dohme, Oeiras, Portugal, 2Hospital de Santo António, Porto, Portugal, 3Hospital 
Beatriz Ângelo, Loures, Portugal, 4Merck Sharp & Dohme, Ballerup, Denmark, 5Merck & Co., North 
Wales, PA, USA, 6Merck & Co., Inc., Whitehouse Station, NJ, USA
objeCtives: HIPOS-ER is an observational, cross-sectional, multicenter study to 
describe the patient population of Type 2 diabetics treated with an anti-hypergly-
cemic agent (AHA) and admitted to the emergency room (ER) with a hypoglycemic 
event. This is the first national hypoglycemia study in Portugal and the first study 
collecting hypoglycemia specific resource data directly in this setting. Here we aim 
to describe the clinical features of hospitalized patients. Methods: The study 
enrolled patients from 7 centers in mainland Portugal for a period of 12 months 
(Jan 2013 – Jan 2014). Sociodemographic and clinical data were collected at the 
emergency room and patients who required hospital admission were followed up. 
Episodes were enrolled consecutively within the sampling period. Results: A total 
of 238 patients were enrolled, and 105 (44%) were hospitalized and 2 (1%) were 
transferred outside the hospital center for likely need of hospitalization. Mean age 
was 78 years, average disease duration was 19 years, 51% were female, 36% were 
on insulin, 51% on a secretagogue, 9% on an oral AHA excluding secretagogue and 
5% on insulin+secretagogue. 26% had complications diagnosed in the ER: Trauma 
(37%) and Cardiovascular (22%) and Infection/Sepsis (22%) were the most frequent. 
Mean and median hospitalization time was 9 and 5 days, respectively. Most (95%) 
patients were admitted to a medical department: Internal medicine (80%) and the ER 
observation/short stay unit (15%) were the most frequent. 6% of patients were admit-
ted to an intensive care unit. 8% (9) of hospitalized patients died. ConClusions: 
Hospitalized diabetic patients following an ER episode due to hypoglycemia were 
treated mainly with secretagogue type drugs. Internal medicine was key in the 
hospital approach of these patients. The length of stay exceeded the 48-72h typical 
surveillance period for secretagogue-induced hypoglycemia. Severe hypoglycemia 
in Portugal is associated with several complications which also include death.
pDB5
comparaTIVe effIcacy anD safeTy of empagLIfLozIn wITh oTher  
anTI-DIaBeTIc Drugs for The TreaTmenT of paTIenTs wITh Type 2 
DIaBeTes meLLITus who are faILIng InsuLIn
Thorlund K.1, Siliman G.1, Eapen S.1, Lund S.2, Palencia R.3
1Redwood Outcomes, Vancouver, BC, Canada, 2Boehringer Ingelheim Pharma GmbH & Co. KG, 
Ingelheim am Rhein, Germany, 3Boehringer Ingelheim GmbH, Ingelheim am Rhein, Germany
objeCtives: The aim of the present network meta-analysis is to compare the effi-
cacy and safety of empagliflozin versus other anti-diabetic drugs, in patients with 
type 2 diabetes mellitus (T2DM) who are inadequately controlled with any insulin 
treatment and with or without other anti-diabetic drugs (ADs). Methods: We 
performed a systematic review of randomized controlled trials (RCTs) and Bayesian 
network meta-analysis to establish the comparative efficacy and safety of SGLT-2s, 
DPP-4s, GLP-1s and TZDs in T2DM patients. The principal outcome of this analysis 
was the effect of these drugs on HbA1c, weight, systolic blood pressure (SBP), inci-
dence of hypoglycaemia and urinary tract infections (UTIs) at 24 weeks. Results: 
Sixteen RCTs were included. All patients received insulin treatment (any type) with 
or without other additional ADs. Compared with placebo, mean changes in HbA1c 
were -0.51 % [95% confidence interval (CI) -0.93 to -0.11%] and -0.60% [95%CI -1.03 to 
-0.19%] for empagliflozin 10mg and 25mg, respectively. HbA1c reduction was similar 
for all other interventions, and no significant differences were detected. Compared 
with placebo, Empagliflozin 10mg and 25mg significantly reduced patients weight by 
approximately -1.5kg. Other SLGT-2s and all GLP-1s were associated with a similar 
weight loss, not change was observed for DPP-4s, and non-significant weight gains 
were observed for TZDs. Empagliflozin was also associated with significant reduc-
tions in SBP, and no significant differences between treatments were detected. For 
hypoglycaemic events, empagliflozin 10mg and 25mg were associated with non-
significant relative risks of 1.03 and 1.23. All interventions had non-significant rela-
tive risks of UTIs. ConClusions: Compared with other treatments, empagliflozin 
comparison, and health economic examples. In the numerical comparison, the 
valuations of all 243 different EQ-5D states and all pure improvements were com-
pared. In the empirical study, a database of 23,925 individuals was used to identify 
patient groups that could be influenced by the implementation of experience-based 
value sets. Two hypothetical health economic examples were used to examine the 
implication of the choice of value set for decision makers. Results: The numeri-
cal comparison showed that only three health states were assigned a lower QALY-
weight in the experience-based value set. The empirical comparison showed that 
severe conditions were assigned higher values in case of experience-based value set. 
Furthermore, the health economic examples showed the choice of a value set has an 
effect on the health economic result. ConClusions: Shifting to experience-based 
QALY-weights would increase the estimated level of quality of life in virtually all 
health conditions. In extension, quality of life enhancing interventions are given 
higher priority in decision making situations where hypothetical values are used to 
construct QALY-weights. On the other hand, in situations where experience-based 
QALY-weights are used, life-prolonging interventions will be prioritised.
research posTer presenTaTIons – sessIon I
DIsease-specIfIc sTuDIes  
DIaBeTes/enDocrIne DIsorDers – clinical outcomes studies
pDB1
hIpos-er (hypogLycemIa In porTugaL oBserVaTIonaL sTuDy – 
emergency room): ouTcomes wITh DIfferenT anTI-hypergLycemIc 
agenTs
Conceição J.1, Laires P.1, Dores J.2, Araújo F.3, Carr R.4, Brodovicz K.5, Radican L.6, Vicente V.7, 
Nogueira A.M.1
1Merck Sharp & Dohme, Oeiras, Portugal, 2Hospital de Santo António, Porto, Portugal, 3Hospital 
Beatriz Ângelo, Loures, Portugal, 4Merck Sharp & Dohme, Ballerup, Denmark, 5Merck & Co., North 
Wales, PA, USA, 6Merck & Co., Inc., Whitehouse Station, NJ, USA, 7Eurotrials, Lisbon, Portugal
objeCtives: HIPOS-ER is an observational study to describe the patient population of 
Type 2 Diabetics treated with an anti-hyperglycemic agent (AHA) and admitted to the 
emergency room (ER) with a hypoglycemic event. In this analysis we aim to describe 
the hypoglycemia events by AHA class. Methods: The study enrolled patients from 7 
centers in mainland Portugal from Jan 2013 – Jan 2014. Sociodemographic and clinical 
data were collected at the emergency room and patients who required hospital admis-
sion were followed up. Episodes were enrolled consecutively within the sampling 
period. AHA therapy classes were Insulin - Group 1, secretagogue based - Group 2, oral 
AHA excluding secretagogue - Group 3 and Insulin+secretagogue – Group 4. Results: 
A total of 238 patients were admitted to the ER with severe hypoglycemia and 105 
(44%) were hospitalized. The distribution based on AHA therapy: 55% (131) Group 1, 
32% (75) Group 2, 7% (16) Group 3 and 7% (16) Group 4. Previous severe hypoglycemia 
in the last 12 months was more frequent in Group 1 vs. Group 2 (p= 0.009). Group 
2 patients were more often followed up in Primary Care vs. Group 1 (84% vs. 48%; 
p< 0.001) and Group 4 (44%, p= 0.002). Group 2 patients were more often hospitalized vs. 
Group 1 (71% vs. 29%; p< 0.001) and Group 4 (31%; p= 0.003). There was no difference in 
terms of the length of stay or hospitalization outcome. 9 deaths occurred: 5 in Group 
1, 3 in Group 2 and 1 in Group 3. ConClusions: In the first national study on severe 
hypoglycemia in Type 2 diabetics, patients treated with Group 2 drugs were followed 
mainly in Primary care setting. More patients on Group 2 drugs were hospitalized. 
Within our sample there is little clinical difference in the hypoglycemia events with 
different therapys besides the need for hospitalization.
pDB2
hIpos-er (hypogLycemIa In porTugaL oBserVaTIonaL sTuDy – 
emergency room): cLInIcaL ouTcomes In The emergency room
Conceição J.1, Dores J.2, Araújo F.3, Laires P.1, Carr R.4, Brodovicz K.5, Radican L.6,  
Nogueira A.M.1
1Merck Sharp & Dohme, Oeiras, Portugal, 2Hospital de Santo António, Porto, Portugal, 3Hospital 
Beatriz Ângelo, Loures, Portugal, 4Merck Sharp & Dohme, Ballerup, Denmark, 5Merck & Co., North 
Wales, PA, USA, 6Merck & Co., Inc., Whitehouse Station, NJ, USA
objeCtives: HIPOS-ER is an observational, cross-sectional, multicenter study to 
characterize the population of Type 2 Diabetics treated with an anti-hyperglycemic 
agent (AHA) who were admitted to the emergency room (ER) with a hypoglycemic 
event. This is the first national ER hypoglycemia study and the first study collecting 
primary resource data in this setting. Here we aim to describe this population and 
the hospital management. Methods: The study enrolled patients from 7 centers 
in mainland Portugal from Jan 2013 – Jan 2014. Sociodemographic and clinical data 
were collected within the emergency room and patients who required hospital 
admission were followed-up. Results: A total of 238 events were recorded. Mean 
age: 76 years; average disease duration: 19 years; 58% female; 80.9% were not 
living alone; 83% no formal education or schooling < 4 years; 25% had a previous 
episode of severe hypoglycemia in the preceding 12 months and 61% were treated 
in a primary care setting. Regarding drug treatment: 55% on insulin; 32% on a 
secretagogue; 7% on other oral AHA and 7% on insulin+secretagogue. Missing a 
meal was the most frequent immediate cause of hypoglycemia (56%). All patients 
received lab evaluations. 71% underwent radiological procedures. Time spent in 
the ER was 11 hours (mean) and the average medical and nurse time utilized was 
85 and 71 min respectively. AHA therapy was changed in 65% of cases: insulin 
adjustment (56%) being the most frequent modification. 56% (132) of patients were 
discharged. ConClusions: Diabetic patients admitted to the ER have several 
markers of frailty and low educational status. Strategies to mitigate hypoglycemia 
underline the need to avoid missed meals. ER episodes are lengthy and consume 
significant physician and nurse time as well as laboratory and other diagnostic 
procedures. Primary care stakeholders should be involved in actions to mitigate 
hypoglycemia in type 2 diabetes.
